Aescin

Aescin, also known as aescinic acid, is an effective mixture of triterpenoid saponins isolated from the dried mature seeds of plants in the horse chestnut family, belonging to the triterpenoid saponin class. Aescin contains many types of saponin compounds. According to Chinese national standards, based on the order of liquid chromatography peaks, they are sequentially named as Aescin A, Aescin B, Aescin C, and Aescin D. They are isomers of each other. Currently, sodium aescinate, used in clinical settings, is a sodium salt mixture composed of Aescin A, Aescin B, Aescin C, Aescin D, and other components. Chemically, it is classified as a natural surfactant and represents the primary bioactive component responsible for the therapeutic properties of horse chestnut. In the pharmaceutical and nutraceutical industries, it is a preferred choice for pharmaceutical-grade gels, tablets, and high-quality cosmetic formulations.

1.Anti-inflammatory and Anti-exudative:

** Aescin inhibits phospholipase A₂, reducing the release of inflammatory mediator precursors. It also suppresses neutrophil adhesion and exudation, thereby alleviating tissue inflammatory responses. Its anti-inflammatory potency is 7-8 times that of hydrocortisone.

2.Anti-edema:

It reduces capillary permeability, decreases fluid accumulation in tissues, and promotes venous return, thus alleviating edema. It demonstrates significant inhibitory effects on traumatic edema, cerebral edema, and venous edema, among others.

3.Increased Venous Tension:

** Aescin enhances venous tension, improves the elasticity of venous walls, and ameliorates lower extremity venous insufficiency. It can be used to treat conditions such as varicose veins and thrombophlebitis.

4.Improved Blood Circulation:

** This agent can dilate blood vessels, increase blood volume, improve local blood circulation, supply more nutrients to tissues, and promote tissue repair and regeneration.

5.Antioxidant:

Aescin possesses the ability to scavenge oxygen free radicals and inhibit lipid peroxidation, protecting cells from oxidative damage and thereby exerting antioxidant effects.

6.Neuroprotective:

In traumatic brain injury models, aescin significantly inhibits the activation of nuclear factor-kappa B and downregulates the protein expression of tumor necrosis factor-alpha. This action reduces cerebral edema and provides a neuroprotective effect.

Environmentally Controlled Process to Preserve Saponin Structure

1.Raw Material Selection: Premium Aesculus hippocastanum seeds (Strict ID & Pesticide Screening).

2.Extraction: Ethanol/Water Solvent Extraction (Low-temperature).

3.Purification: Column Chromatography to remove impurities and enrich Aescin content.

4.Concentration & Crystallization: Precise control to achieve 98% purity.

5.Drying: Spray Drying / Vacuum Drying.

6.Milling & Sifting: 80 Mesh standard.

7.Quality Control: HPLC Assay & Heavy Metal Testing.

8.Packing: Inner PE bag + Outer Fiber Drum.

Product: Aescin 98% (Pharma Grade)

We utilize High-Performance Liquid Chromatography (HPLC) or Titration (depending on client requirement/pharmacopoeia EP/USP) to verify the Aescin content.

• This method separates the Aescin isomers (Aescin Ia, Ib, Isoaescin) to ensure the total saponin content meets the 98% label claim, avoiding falsification with cheaper, non-active fillers.

**Determination of Aescin Content**

1. Titrimetric Assay for Total Aescin
Weigh accurately about 0.5 g of the substance, dissolve in 5 ml of water, add 10 ml of ethanol, and mix. Add 2–3 drops of phenolphthalein indicator solution, then titrate with sodium hydroxide volumetric solution (0.01 mol/L) until a pink color appears. Precisely add 10 ml of sodium hydroxide volumetric solution (0.2 mol/L), mix, heat under reflux for 4 hours, and allow to cool. Rinse the condenser and flask mouth with 2 ml of ethanol. Titrate with hydrochloric acid volumetric solution (0.1 mol/L), and perform a blank test for correction. Each 1 ml of sodium hydroxide volumetric solution (0.2 mol/L) is equivalent to 113.00 mg of C₅₅H₈₆O₂₄.

2.Determination of Aescin A and Aescin B

Perform the test according to High-Performance Liquid Chromatography (Appendix V D, Part II, Chinese Pharmacopoeia 2000).

Chromatographic Conditions and System Suitability**

Use octadecylsilane-bonded silica gel as the stationary phase and a mixture of acetonitrile–phosphoric acid solution (prepared by diluting 5.5 ml of 85% phosphoric acid with water to 1000 ml) (33:67) as the mobile phase. Adjust the pH to 2.1. The detection wavelength is 220 nm. The number of theoretical plates calculated for aescin A should not be less than 5,000, and the resolution between aescin A and aescin B should meet the requirements.

Preparation of Test Solution

Dissolve an appropriate amount of the substance in methanol and dilute to obtain a solution containing 2.5 mg per 1 ml.

**Preparation of Reference Solution**

Dissolve an appropriate amount of aescin reference substance in methanol and dilute to obtain a solution containing 2.5 mg per 1 ml.

Assay Procedure

Inject 20 µl of the reference solution into the liquid chromatograph. The chromatogram of the reference solution shows four main peaks, identified in order of elution as aescin A, aescin B, aescin C, and aescin D. Separately, inject 20 µl of the test solution into the liquid chromatograph. Measure the peak areas corresponding to aescin A and aescin B in the test solution relative to the reference solution. Calculate the contents of aescin A and aescin B by the external standard method using peak areas.

Stability Studies

Our Aescin 98% supports a 24-month shelf life when stored properly.

• Long-term Stability: (25°C ± 2°C / 60% RH) - All parameters (Assay, Appearance, LOD) remained within specification for 24 months.

• Accelerated Stability: (40°C ± 2°C / 75% RH) - Tested for 6 months.

• Consistency: The critical quality attributes tested (Assay 98%, Appearance: White Powder, Water Content) are strictly consistent with the Module 6 Quality Standard table. No significant degradation was observed, ensuring the product remains potent during global transport.

Safety & Handling (MSDS Summary)

• Classification: Generally considered safe for intended industrial use; refer to specific regulations for final dosage forms.

• Handling: Wear safety glasses, gloves, and dust masks (N95) to avoid inhalation of fine powder. Avoid contact with eyes.

• Storage: Store in a cool, dry place (away from direct light). Keep the container tightly closed (Polyethylene bag inside, fiber drum outside).

1.Sirtori, C. R. (2001). Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacological Research, 44(3), 183-193.

2.Pittler, M. H., & Ernst, E. (2012). Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database of Systematic Reviews.

3.Dudek-Makuch, M., & Studzińska-Sroka, E. (2015). Horse chestnut – efficacy and safety in chronic venous insufficiency: an overview. Revista Brasileira de Farmacognosia.

4.Domanski, D., et al. (2016). Anti-inflammatory and anti-edematous effects of Aescin. Journal of Inflammation Research.

5.European Medicines Agency (EMA). (2020). Assessment report on Aesculus hippocastanum L., semen.